Table 1 Objectives of the PATHFINDER Registry and future perspectives

Specific objectives

 Drug therapy

Monitoring and documenting the therapeutic regimen, encompassing ACE inhibitors, AT blockers, ARNIs, beta-blockers, MRAs, diuretics, SGLT2 inhibitors, soluble guanylate cyclase stimulators (e.g., Vericiguat), digitalis glycosides, and pulmonary-vasoactive agents

 Personalized precision medicine

Developing algorithms for personalized precision medicine through the utilization of pattern recognition methodologies

 Medical devices

Monitoring and documenting treatment outcomes following implantation of pacemaker systems, cardiac resynchronization therapy, post-implantable cardioverter-defibrillator (ICD) interventions, and cardiac contractility modulation (CCM) devices

 Interventions

Documenting post-procedural outcomes subsequent to interventional or surgical interventions

 Assist devices

Monitoring and documenting patient progress with assistive devices

 Transplantation

Documenting clinical course of patients awaiting transplantation, and after transplantation

 Clinical warning signs

Evaluating safety profiles of therapeutic interventions and identifying risk patterns, including early indicators

Future perspectives

 Prevention

Development of preventive measures to avoid clinical deterioration and heart failure

 Prehabilitation

Establishing appropriate prehabilitation programs within existing rehabilitation facilities to prepare patients for more complex cardiac operations or interventions with health-promoting measures

 Rehabilitation

Developing and expanding appropriate rehabilitation measures within experienced facilities to optimize functioning and reduce disability in interaction with their environment

 Disease programs

Integrating ACHD management into targeted preventive health programs